They have made massive progress.
However, as far as ongoing revenue is concerned, it's only FebriDx with ViraDx as a loss leader.
In a small market until the CLIA waiver gets FDA greenlit and sales teams get cracking. That's 12 - 18 months away
There won't be any significant recurring IP money coming in until the 'royalty' agreements are signed - 18 months away.
Will BARDA make a contract offer? - 18 - 24 months away.
When Burnett and Hologic puts pen to paper on those then LDX will issue a quite meaty guidance figure.
Until then, we wait.
It's frustrating, but that's the game we chose to play.
Again, the RRR is heavily skewed in our favour. If you wait.
Add to My Watchlist
What is My Watchlist?
